Skip to main content

Table 1 Baseline characteristics of 83 patients at the time of colonoscopy

From: Expression of Cyr61 is associated with clinical course in patients with Crohn’s disease

 

Patients without clinical recurrence (n = 54)

Patients with clinical recurrence (n = 29)

P value

Age, years., (mean ± SD)

31.6 ± 11.1

28.4 ± 9.9

0.21

Male, n (%)

40 (74.1%)

22 (75.9%)

0.86

Disease duration, years, median (range)

4.0 (0.0 ~ 15.0)

3.0 (0.0 ~ 12.0)

0.06a

Location of disease (Montreal classification), n (%)

  

0.54

 Ileum (L1)

4 (7.4%)

2 (6.9%)

 

 Colon (L2)

2 (3.7%)

1 (3.4%)

 

 Ileocolon (L3)

48 (88.9%)

24 (82.8%)

 

 Concomitant UGI disease (L4)

0 (0.0%)

2 (6.9%)

 

Medication at the time of colonoscopy, n (%)

   

 5-ASA

42 (77.8%)

19 (65.5%)

0.23

 Systematic steroid

0 (0.0%)

2 (6.9%)

0.12b

 Azathioprine/6-mercaptopurine

19 (35.2%)

5 (17.2%)

0.09

 TNF-α antagonist

4 (7.4%)

3 (10.3%)

0.70b

CDAI, median (range)

100 (2–328)

171 (41–470)

 < 0.01a

CDEIS, median (range)

4.0 (0.25–31.5)

4.0 (0.25–31.0)

0.50a

SES-CD, median (range)

5.0 (1.0–36.0)

5 (1–27)

0.33a

  1. SD standard deviation, 5-ASA 5-aminosalicylic acid, CDAU Crohn’s disease activity index, CDEIS Crohn’s disease index of severity, SES-CD simple endoscopic score for Crohn’s disease
  2. aMan–Whitney U test
  3. bFisher’s exact test